Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market: Latest Study by DelveInsight Reveals a Lucrative Investment Opportunity and Growth Prospect | Eidos Therapeutics, NeuraImmune Therapeutics, Alexion Pharmaceuticals, NeuraImmune Therapeutics, Pfizer, I

As per DelveInsight, the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market is anticipated to evolve immensely in the coming years owing to the increasing prevalent population of transthyretin amyloid cardiomyopathy patients in the 7MM and the expected entry of the emerging therapies in the market.

DelveInsight's "Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Transthyretin Amyloid Cardiomyopathy Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Transthyretin Amyloid Cardiomyopathy therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Transthyretin Amyloid Cardiomyopathy treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM): An Overview
buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues. ATTR amyloidosis can impact numerous organs and tissues in the body, including the peripheral nervous system, and organs such as the heart, kidneys, gastrointestinal tract, and eyes.

According to the World Heart Federation, transthyretin amyloid cardiomyopathy (ATTR-CM) is a presentation of ATTR amyloidosis that primarily affects the heart. In ATTR-CM the amyloid fibrils get accumulated in the myocardium.

There are two forms of ATTR-CM, hereditary or variant (hATTR) and wild-type (wtATTR). The hereditary form of ATTR-CM is inherited and caused by a mutation in the transthyretin (TTR) gene, which results in an unstable TTR protein that dissociates and misfolds, forming amyloid, while the wild-type form of ATTR-CM is a result of age-related changes in wild-type TTR stability, and it occurs after age 60.

ATTR-CM may be suspected during the routine cardiac test-an electrocardiogram or echocardiogram. When suspected, more specialized tests are needed to confirm the diagnosis, which includes imaging studies of the heart, most commonly a cardiac MRI and/or a nuclear medicine scan of the heart, tissue biopsy, and genetic testing.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Key Facts
• ATTR-CM is often underdiagnosed or misdiagnosed; it is believed that only 1-2% of people with the disease are diagnosed.
• According to the American Heart Association, hereditary ATTR-CM is more common in localized parts of Portugal, Sweden, and Japan.
• According to the article by Inserro (2019), the estimated prevalent cases of ATTR-CM in the US is 100,000, and only 1-2% of these are diagnosed.
• According to the study by Winburn et al. titled "Estimating the Prevalence of Transthyretin Amyloid Cardiomyopathy in a Large In-Hospital Database in Japan," the diagnosed prevalence in Japan was 191.1 per million for wild-type ATTR-CM and 3.2-5.1 per million for hereditary ATTR-CM.
• As per the study by Damy et al. titled "Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness," out of 298 patients with left ventricular wall thickness, 17 (5.7%) patients had TTR mutations of whom 15 (5.0%) had hereditary ATTR-CM.

Discover How Transthyretin Amyloid Cardiomyopathy Market Will Grow by 2032:
https://www.delveinsight.com/report-store/transthyretin-amyloid-cardiomyopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Transthyretin Amyloid Cardiomyopathy therapies in the market. It also provides a detailed assessment of the Transthyretin Amyloid Cardiomyopathy market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the market trend for each marketed Transthyretin Amyloid Cardiomyopathy drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Epidemiology
The epidemiology section covers detailed insights into the historical, and current Transthyretin Amyloid Cardiomyopathy patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Transthyretin Amyloid Cardiomyopathy Epidemiology Segmented as -
• Total Prevalent Population of Transthyretin Amyloid Cardiomyopathy in the 7MM [2019-2032]
• Type‐specific Prevalent Population of Transthyretin Amyloid Cardiomyopathy in the 7MM [2019-2032]
• Diagnosed and Treatable Population of Transthyretin Amyloid Cardiomyopathy in the 7MM [2019-2032]

Get Key Insights Into the Evolving Transthyretin Amyloid Cardiomyopathy Epidemiology Trends @
https://www.delveinsight.com/report-store/transthyretin-amyloid-cardiomyopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Transthyretin Amyloid Cardiomyopathy market or expected to be launched during the study period. The analysis covers the market share by Transthyretin Amyloid Cardiomyopathy drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Transthyretin Amyloid Cardiomyopathy Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities @
https://www.delveinsight.com/sample-request/transthyretin-amyloid-cardiomyopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Transthyretin Amyloid Cardiomyopathy (ATTR-CM). Currently, NeuraImmune Therapeutics is leading the therapeutics market with its Transthyretin Amyloid Cardiomyopathy (ATTR-CM) drug candidates in the mid to advanced stage of clinical development.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Companies in the Therapeutics Market Include:
• Eidos Therapeutics
• NeuraImmune Therapeutics
• Alexion Pharmaceuticals
• NeuraImmune Therapeutics
• Pfizer
• Ionis Pharmaceuticals
• Akcea
• Alnylam Pharmaceuticals
And Many Others

Emerging and Marketed Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Therapies Covered in the Report Include:
• Acoramidis (AG 10): Eidos Therapeutics/Alexion Pharmaceuticals
• NI006: NeuraImmune Therapeutics
• Vyndaqel (tafamidis meglumine): Pfizer
• Vyndamax (tafamidis): Pfizer
• Eplontersen: Ionis Pharmaceuticals/Akcea
• Vutrisiran: Alnylam Pharmaceuticals
And Many More

Learn More About the Emerging Therapies & Key Companies in the Transthyretin Amyloid Cardiomyopathy Therapeutics Market:
https://www.delveinsight.com/sample-request/transthyretin-amyloid-cardiomyopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Transthyretin Amyloid Cardiomyopathy Competitive Intelligence Analysis
4. Transthyretin Amyloid Cardiomyopathy Market Overview at a Glance
5. Transthyretin Amyloid Cardiomyopathy Background and Overview
6. Transthyretin Amyloid Cardiomyopathy Patient Journey
7. Transthyretin Amyloid Cardiomyopathy Epidemiology and Patient Population
8. Transthyretin Amyloid Cardiomyopathy Treatment Algorithm, Current Treatment, and Medical Practices
9. Transthyretin Amyloid Cardiomyopathy Unmet Needs
10. Key Endpoints of Transthyretin Amyloid Cardiomyopathy Treatment
11. Transthyretin Amyloid Cardiomyopathy Marketed Products
12. Transthyretin Amyloid Cardiomyopathy Emerging Therapies
13. Transthyretin Amyloid Cardiomyopathy Seven Major Market Analysis
14. Attribute Analysis
15. Transthyretin Amyloid Cardiomyopathy Market Outlook (7 major markets)
16. Transthyretin Amyloid Cardiomyopathy Access and Reimbursement Overview
17. KOL Views on the Transthyretin Amyloid Cardiomyopathy Market.
18. Transthyretin Amyloid Cardiomyopathy Market Drivers
19. Transthyretin Amyloid Cardiomyopathy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/transthyretin-amyloid-cardiomyopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market
https://www.delveinsight.com/report-store/blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-market

Chronic Idiopathic Constipation Market
https://www.delveinsight.com/report-store/chronic-idiopathic-constipation-market

Hay Fever Conjunctivitis Market
https://www.delveinsight.com/report-store/hay-fever-conjunctivitis-market

Nasopharyngeal Carcinoma Market
https://www.delveinsight.com/report-store/nasopharyngeal-carcinoma-market

Cerebral Infarction Market
https://www.delveinsight.com/report-store/cerebral-infarction-market

CART-related Neurotoxicity (NT) Market
https://www.delveinsight.com/report-store/cart-related-neurotoxicity-nt-market

Hernia Repair Devices Market
https://www.delveinsight.com/report-store/hernia-repair-devices-market

Bronchial Hyperreactivity Market
https://www.delveinsight.com/report-store/bronchial-hyperreactivity-market

Chronic Focal Epilepsy Market
https://www.delveinsight.com/report-store/chronic-focal-epilepsy-market

Dental Lasers Market
https://www.delveinsight.com/report-store/dental-lasers-market

Down Syndrome Market
https://www.delveinsight.com/report-store/down-syndrome-market

Extracorporeal Circulation System Market
https://www.delveinsight.com/report-store/extracorporeal-circulation-system-market

Failed Back Surgery Syndrome Market
https://www.delveinsight.com/report-store/failed-back-surgery-syndrome-market

Germ Cell Tumor Market
https://www.delveinsight.com/report-store/germ-cell-tumor-market

Hot Flashes Market
https://www.delveinsight.com/report-store/hot-flashes-market

India Healthcare Outlook
https://www.delveinsight.com/report-store/india-healthcare-outlook-report

Insulin Glargine Biosimilar
https://www.delveinsight.com/report-store/insulin-glargine-biosimilar-insight

Listeriosis Market
https://www.delveinsight.com/report-store/listeriosis-market

Liver Angiosarcoma Market
https://www.delveinsight.com/report-store/liver-angiosarcoma-market

Mucopolysaccharidosis I Market
https://www.delveinsight.com/report-store/mucopolysaccharidosis-i-market

Nasolabial Fold Market
https://www.delveinsight.com/report-store/nasolabial-fold-market

Neuroleptic Malignant Syndrome Market
https://www.delveinsight.com/report-store/neuroleptic-malignant-syndrome-market

Pachyonychia Congenita Market
https://www.delveinsight.com/report-store/pachyonychia-congenita-market

Point of Care Glucose Testing Market
https://www.delveinsight.com/report-store/point-of-care-glucose-testing-market

Reactive Airway Disease Market
https://www.delveinsight.com/report-store/reactive-airway-disease-market

Seborrhea Market
https://www.delveinsight.com/report-store/seborrhea-market

Substance (Drug) Abuse Market
https://www.delveinsight.com/report-store/substance-drug-abuse-market

Synchronous Endometrial and Ovarian Cancer (SEOC) Market
https://www.delveinsight.com/report-store/synchronous-endometrial-and-ovarian-cancer-seoc-market

Trastuzumab Biosimilars
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight

Urinary Tract Infection Devices Market
https://www.delveinsight.com/report-store/urinary-tract-infection-devices-market

Varicose Veins Market
https://www.delveinsight.com/report-store/varicose-veins-market

Vulvodynia Market
https://www.delveinsight.com/report-store/vulvodynia-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.